Human Reproduction Update, Vol.5, No.6 pp.721-735, 1999
© European Society of Human Reproduction and Embryology 1999; all rights reserved
Interpretations. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks
0 UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research, World Health Organization, Avenue Appia 20, CH-1211 Geneva 27, Switzerland 1 Department of Obstetrics and Gynecology, McMaster University, Hamilton, Canada z Corresponding author
Abstract
Cardiovascular risks have been a concern since combined oral contraceptives (OCs) were first introduced. In the past four years new, mostly reassuring information on the safety of modern, low oestrogen dose OCs has become available. However, in 1995 the new information showed higher venous thromboembolism (VTE) risk for OCs containing desogestrel and gestodene compared with levonorgestrel-or norethindrone-containing OCs. The controversial responses by national authorities, their scientific and public health merits were hotly debated and many considered the differences in risk small and resulted from bias and/or confounding. We discuss these arguments and conclude they lack empirical support or cannot account for the 2-fold increased risk. The risk of ischaemic stroke and myocardial infarction (MI) associated with low oestrogen dose OCs are very small in women without cardiovascular risk factors, while increased risk of haemorrhagic stroke is confined to women >35 years of age. Applying the most recent risks to models of OC-attributable events and deaths, OC-attributable mortality in women <35 years is estimated to be <3 per million users annually, rising to about 10 per million users annually among smokers. In the context of external cause mortality (about 90 per million women of reproductive age annually in the UK) such risks appear small. Over the age of 35 years, OC-attributable mortality is a more important concern, particularly among smokers. In the absence of any appreciable OC-attributable mortality in young healthy women, the additional VTE risk for third compared with second generation OCs should be considered when women choose which OC to use.
Key words: myocardial infarction/oral contraceptives/stroke/vascular risks/venous thromboembolism
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Sitruk-Ware New progestagens for contraceptive use Hum. Reprod. Update, March 1, 2006; 12(2): 169 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. V. Gomes and S. R. Deitcher Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy: A Clinical Review Arch Intern Med, October 11, 2004; 164(18): 1965 - 1976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Alexandersen, J. Haarbo, P. Zandberg, J. Jespersen, S. O. Skouby, and C. Christiansen Lack of difference among progestins on the anti-atherogenic effect of ethinyl estradiol: a rabbit study Hum. Reprod., July 1, 2003; 18(7): 1395 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Girolami, L. Spiezia, F. Vianello, B. Girolami, and F. Fabris Changes in Prescription Patterns of Oral Contraceptives in a Northern Italian Province: Relation With Venous Thromboembolism Clinical and Applied Thrombosis/Hemostasis, April 1, 2003; 9(2): 125 - 130. [Abstract] [PDF]
|
|
|
|
 |
|
 D. C G Skegg Oral contraceptives, venous thromboembolism, and the courts BMJ, September 7, 2002; 325(7363): 504 - 505. [Full Text] [PDF]
|
|
|
|
|
|
A. Girolami, L. Spiezia, B. Girolami, and F. Vianello Tentative Guidelines and Practical Suggestions to Avoid Venous Thromboembolism During Oral Contraceptive Therapy Clinical and Applied Thrombosis/Hemostasis, April 1, 2002; 8(2): 97 - 102. [Abstract] [PDF]
|
|
|
|
|
|
A. Girolami, L. Spiezia, F. Rossi, and E. Zanon Oral Contraceptives and Venous Thromboembolism: Which Are the Safest Preparations Available? Clinical and Applied Thrombosis/Hemostasis, April 1, 2002; 8(2): 157 - 162. [Abstract] [PDF]
|
|
|
|
 |
|
 F.R. Rosendaal, F.M. Helmerhorst, and J.P. Vandenbroucke Female Hormones and Thrombosis Arterioscler. Thromb. Vasc. Biol., February 1, 2002; 22(2): 201 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M Kemmeren, A. Algra, and D. E Grobbee Third generation oral contraceptives and risk of venous thrombosis: meta-analysis BMJ, July 21, 2001; 323(7305): 131 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Vandenbroucke, J. Rosing, K. W.M. Bloemenkamp, S. Middeldorp, F. M. Helmerhorst, B. N. Bouma, and F. R. Rosendaal Oral Contraceptives and the Risk of Venous Thrombosis N. Engl. J. Med., May 17, 2001; 344(20): 1527 - 1535. [Full Text] [PDF]
|
|
|
|
|
|
H. Jick, J. A Kaye, C. Vasilakis-Scaramozza, and S. S Jick Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis BMJ, November 11, 2000; 321(7270): 1190 - 1195. [Abstract] [Full Text]
|
|
|
|
|
|
D. C G Skegg Third generation oral contraceptives BMJ, July 22, 2000; 321(7255): 190 - 191. [Full Text]
|
|